Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF G469A |
| Therapy | Erlotinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF G469A | lung non-small cell carcinoma | predicted - sensitive | Erlotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tarceva (erlotinib) inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in 2D and 3D culture (PMID: 39637338). | 39637338 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39637338) | Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations. | Full reference... |